Products

9-Anthraceneboronic acid

9-Anthraceneboronic acid

9-Anthraceneboronic acid

CAS No.: 100622-34-2

Category Products

Cat.NO.:A112579 Purity:98%

Product Details of [ 100622-34-2 ]

CAS No. :	100622-34-2
Formula :	C₁₄H₁₁BO₂
M.W :	222.05
SMILES Code :	OB(C1=C2C=CC=CC2=CC3=CC=CC=C13)O
MDL No. :	MFCD03425925
InChI Key :	VHHDLIWHHXBLBK-UHFFFAOYSA-N
Pubchem ID :	15510213

Safety of [ 100622-34-2 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H317-H319
Precautionary Statements:	P280-P305+P351+P338

Computational Chemistry of [ 100622-34-2 ] Show Less

Physicochemical Properties

Num. heavy atoms	17
Num. arom. heavy atoms	14
Fraction Csp3	0.0
Num. rotatable bonds	1
Num. H-bond acceptors	2.0
Num. H-bond donors	2.0
Molar Refractivity	71.28
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	40.46 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	0.0
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	3.33
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	1.67
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	2.26
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	1.39
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	1.73

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-3.86
Solubility	0.0308 mg/ml ; 0.000139 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-3.86
Solubility	0.0309 mg/ml ; 0.000139 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-4.65
Solubility	0.00501 mg/ml ; 0.0000225 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Moderately soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	Yes
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	Yes
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-5.29 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	0.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	2.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12’782’590 molecules and tested on 40 external molecules (r² = 0.94)	1.98

Application In Synthesis of [ 100622-34-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 100622-34-2 ]

[ 100622-34-2 ] Synthesis Path-Downstream 1~4

1
[ 100622-34-2 ]
[ 2620-76-0 ]
[ 944801-79-0 ]

Yield	Reaction Conditions	Operation in experiment
73%	With tetrakis(triphenylphosphine) palladium(0); potassium carbonate; In tetrahydrofuran; water; for 5h;Reflux; Inert atmosphere;	In the flask, 9-indoleboronic acid (5 g, 22 mmol) was added.<strong>[2620-76-0]2-(4-bromophenyl)-1-phenyl-1H-benzimidazole</strong> (7.9 g, 22 mmol),Potassium carbonate (6g, 44mmol),Tetrahydrofuran (100mL),Water (50mL),Tetrakistriphenylphosphine palladium (0.5g),Heated under nitrogen for 5 hours,cool down,The crude product was purified by column chromatography to give 7.1 g,The yield was 73%.

References: [1]Journal of Materials Chemistry,2011,vol. 21,p. 2957 – 2964.
[2]Patent: CN108752317,2018,A .Location in patent: Paragraph 0054; 0055; 0056.

2
[ 19063-56-0 ]
[ 100622-34-2 ]
7-(anthracen-9-yl)-2H-chromen-2-one [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
28%	With tetrakis(triphenylphosphine) palladium(0); potassium carbonate; In tetrahydrofuran; water; for 48h;Reflux;	Intermediate 4-1 (0.300 g, 1.33 mmol), anthracen-10-yl-10-boronic acid (1.60 mmol), and tetrakis(triphenylphosphine)palladium (0) (0.077 g, 0.07 mmol) were added to a 100 mL round-bottom flask, and a mixture of THF and 2 normal (N) K2CO3 aqueous solution (2:1 (v/v)) was added thereto, and the mixed solution was refluxed for 2 days. After completion of the reaction, water was poured into the reaction mixture, and the resulting mixture was cooled. An organic layer extracted therefrom by using CH2Cl2 (100 mL*4 times) was dried with MgSO4, and concentrated. The resulting product thus obtained was purified by silica gel chromatography while increasing the polarity of the eluent from CH2Cl2:n-hexane (at 1:2 (v/v)) to CH2Cl2:n-hexane (at 1:1 (v/v)), thereby obtaining Compound 4 (yellow powder, yield of 28%). 1H NMR (300 MHz, CDCl3) delta: 6.55 ppm (d, J=9.6 Hz, 1H), 7.35-7.41 ppm (m, 3H), 7.46-7.51 ppm (m, 3H), 7.59-7.62 ppm (m, 2H), 7.70 ppm (d, J=7.5 Hz, 1H), 7.88 ppm (d, J=9.6 Hz, 1H), 8.08 ppm (d, J=8.4 Hz, 2H), 8.56 ppm (s, 1H). 13C NMR (126 MHz, CDCl3) delta: 117.00 ppm, 118.31 ppm, 119.79 ppm, 125.43 ppm, 126.12 ppm, 126.17 ppm, 127.68 ppm, 127.93 ppm, 128.69 ppm, 129.96 ppm, 131.40 ppm, 134. 62 ppm, 143.40 ppm, 143.44 ppm, 154.29 ppm, 160.87 ppm.

References: [1]Journal of Materials Chemistry C,2016,vol. 4,p. 4556 – 4567.
[2]Patent: US2019/74445,2019,A1 .Location in patent: Paragraph 0215-0218.

3
[ 1564-64-3 ]
[ 100622-34-2 ]
[ 1055-23-8 ]

References: [1]Angewandte Chemie – International Edition,2016,vol. 55,p. 13052 – 13055.

Angew. Chem.,2016,p. 13052 – 13055,4.

4
[ 100622-34-2 ]
[ 84539-22-0 ]
C₂₂H₁₉N₃O [ No CAS ]

References: [1]Chemical Science,2019,vol. 10,p. 8825 – 8831.

Details

Reviews

There are no reviews yet.

Be the first to review “9-Anthraceneboronic acid”

Previous

Pyridoxine Impurity A

Next

4-Amino-1-methylpyrazole-3-carboxylic acid